Camposol 3Q 2023 Earnings Conference Call Unsecured notes due 2027

November 2023





Disclaimer



This presentation does not provide full disclosure of all material facts relating to Camposol Holding PLC and its direct or indirect subsidiaries, including but not limited to Camposol S.A., a sociedad anónima organized under the laws of Peru (together, the "Company" or "Camposol"), the securities of Camposol or a potential offering of such securities and is not subject to liability for misrepresentations under applicable securities legislation.

The contents hereof should not be construed as investment, legal, tax or other advice and you should consult your own advisers as to legal, business, tax and other related matters concerning an investment in Camposol

This presentation does not constitute a prospectus and should under no circumstances be understood as an offer to sell or the solicitation of an offer to buy securities nor will there be any sale of securities in any state, province or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Such an offer or solicitation can only be made by way of an effective registration statement or prospectus in accordance with the securities laws.

Certain statements herein are "forward-looking statements." Statements contained herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "continues," "expect," "estimate," "intend," "plans," "project," "target," and similar expressions and future or conditional verbs such as "will," "would," "should," "could," "might," "potential," "can," "may," or the negative of these terms or similar expressions are generally intended to identify forward-looking statements. These forward-looking statements speak only as of the date hereof and are based on Camposol's current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond Camposol's control. As a consequence, current plans, anticipated actions and future financial position and results of operations may differ significantly from those expressed in any forward-looking statements in the presentation. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented and we do not intend to update any of these forward-looking statements.


No representation or warranty is given in respect of the information contained herein, and neither the delivery of this presentation nor any investment in Camposol securities will under any circumstances create any implication that Camposol has updated the information contained herein. Information throughout the presentation provided by sources other than Camposol has not been independently verified. Differences between past performance and actual results may be material and adverse.

This presentation includes unaudited non-IFRS financial measures, including Adjusted EBITDA and Adjusted EBITDA Margin. We present non-IFRS measures when we believe that the additional information is useful and meaningful to investors. Non-IFRS financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similar measures presented by other companies. The presentation of non-IFRS financial measures is not intended to be a substitute for, and should not be considered in isolation from, the financial measures reported in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board.

Neither this presentation nor the information contained herein may be copied, reproduced, disclosed or distributed in whole or in part at any time without the prior written consent of Camposol. By accepting this presentation, the recipient acknowledges and agrees that this presentation and all of the information contained herein is confidential and subject to the confidentiality email previously acknowledged by the recipient. Without limiting the generality of the foregoing, the recipient will not reproduce this presentation in whole or in part and will hold all information contained in this presentation and the fact that Camposol is considering a potential initial public offering in confidence.

Speakers Today





Operational Overview

Summary

- Total volume sold as of closing September 2023 decreased by 2.6% compared to the same period last year, mainly driven by lower blueberry volume.
- Total sales amounted to USD 264.6 million, down 3.7% compared to the same period last year. Mango, grape and tangerine were the crops that experienced reduced sales.
- EBITDA from continuing operations amounted to USD 52.3 million as of closing September 2023, up 32.7% compared to the same period in 2022. EBITDA margin from continued operations as of closing 2023 increased to 19.7% from 14.3% in the same period last year.
- LTM EBITDA as of September 30th, 2023, amounted to USD 75.0 million.
- The directive of prioritizing capital investments, including maintenance capex for crops and short-term growth capex to alleviate cash pressure, has been diligently followed. This aligns with the strategic objective defined at the beginning of the year
- We have continued our plan to manage our total debt, having restructured short-term debt into long-term debt by USD 80 million. Over the next few months, we will continue managing our total debt level as payments from the blueberry campaign are collected.






Operational overview

Summary

Operational overview YTD 3Q 2023






Highlights

- YTD volume sold by closing Q3 shows a 2.6% decrease compared to last year, mainly driven by blueberry segment.
- YTD Revenue amount to USD 264.6 million, driven by higher sales levels in the blueberry and avocado segments, offsetting the lower sales in other crops.
- YTD EBITDA amount to USD 52.36 million, which is 32.68% higher than the same period last year.
- This improvement has been facilitated not only by an improved market for the blueberry segment but also by reduced freight expenses and a decrease expenditures related to third-party services.
- Additionally, we have taken steps to reorganize our work teams, achieving a more efficient and cohesive operational structure. This strategic adjustment allows us to focus on enhancing crop performance and advancing our long-term strategic initiatives.

Operational overview YTD 3Q 2023





Highlights

Throughout the second half of the year, atypical weather conditions—specifically, a warmer-than-usual winter with occasional temperatures surpassing historical averages by 3 degrees Celsius— affected our crops. These conditions led to campaign delays and a reduction in overall volume.

- During the first nine months of this year, our volume sold decreased by 12.8%, while the average price rose by 18.9%, both in comparison to the corresponding period in 2022. In the third quarter alone, the volume saw a significant 46.1% decline, yet the average price surged by 55.7% compared to the same quarter in 2022. Despite the substantial volume reduction, the favorable pricing environment offset this effect, resulting in a 3.7% sales growth compared to the first nine months of 2022
 - During the first nine months of the year, despite selling a higher volume than in 2022 by 13.6%, we obtained a lower price by 11.1%. This outcome resulted from campaign delays and an overlap with volume coming from Mexico



During the first nine months of this year, our volume sold dropped by 6.2%, and the average price declined by 26.3%. This decline is attributed to quality issues; the fruit did not fully transition from green to orange, due to the prolonged warmer temperatures.

Liquidity & capital structure - cash flow



	<u>30.09.23</u>	<u>31.12.22</u>	30.09.22
Cash flow from operating activities			
Collections	325,063	431,239	265,902
Payment to suppliers and employees	(261,689)	(416,903)	(276,531)
Interest paid	(31,749)	(24,232)	(21,346)
Income tax paid	(7,623)	(6,743)	(5,756)
Custom duties refund collections	2,213	3,193	1,758
Other payments	(1,024)	(706)	(671)
Net cash (used in) provided by operating activities	25,191	(14,152)	(36,644)

Cash flow from investing activities			
Purchases of property, plant and equipment	(10,030)	(24,690)	(18,321)
Investment in biological assets	(24,756)	(47,756)	(25,751)
Purchases of intangibles, excluding goodwill	(539)	(2,499)	(1,399)
Dividends from associates	597	1,864	-
Loans granted to related parties	612	(1,000)	(964)
Proceeds from sale of property, plant and equipment	106	100	24
Net cash used in investing activities	(34,010)	(73,981)	(46,411)

Cash flow from financial activities			
Bank loans proceeds	465,221	439,100	314,992
Bank loans payments	(528,000)	(307,050)	(187,950)
Dividends distribution	-	(35,000)	(35,000)
Principal elements of lease liabilities payments	(6,908)	(11,657)	(10,458)
Long-term debt proceeds	73,522	-	-
Payments of long-term debt	-	(513)	(513)
Net cash provided by financial activities	3,835	84,880	81,071
Net (decrease) increase in cash during the period	(4,984)	(3,253)	(1,984)
Cash and cash equivalents at beginning of period	27,222	30,475	30,475
Cash and cash equivalents at end of period	22,238	27,222	28,491


Comments

- The operating cash flow at the close of September 2023 is significantly better than that of 2022. This improvement is not only due to a more favorable logistical cost context throughout the year but also a result of ongoing efforts to reduce collection days. This has been effective in more efficiently covering the assumed interest costs
- Our capital expenditure strategy remains focused on executing short-term maintenance and growth capex.
- We have disbursed leasebacks for \$80 million in medium-term financing to partially replace short term debt.

Liquidity & capital structure - leverage & debt profile




Net Debt / EBITDA



Debt profile

- Long-term debt: USD 441 mm
- Duration: ~ 5 years



Comments

- During the first nine months of 2023, we were able to restructure USD 80 million in debt towards the medium-term. This helped alleviate the short-term pressure on our cashflow.
- Net debt to EBITDA ratio still higher, keep the positive trend.

1. Includes short & long term debt without capitalized fees and interest

Operational overview

Summary

Summary

- We will persist in seeking comprehensive operational efficiencies across the organization to further enhance the company's performance.
- We will maintain our focus on liquidity and financial flexibility, aligning with our strategic approach of executing only short-term maintenance and growth capex, while concurrently reducing the company's debt levels in the upcoming months



Operational overview

Summary

Financial statements - Income statement

|--|

	For the period ended	
CONTINUED OPERATIONS	30.09.2023*	30.09.22*
Revenue	264,607	274,700
Cost of sales	(190,899)	(200,572)
Cost of sales	(167,823)	(178,343)
Depreciation of bearer plants	(23,076)	(22,229)
Impaiment of fixed assets	-	-
Gross profit before adjustment for biological assets	73,708	74,128
Net adjustment from change in fair value of biological	(2,983)	(25,885)
Profit after adjustment from biological assets	70,725	48,243
Selling expenses	(43,656)	(54,196)
Administrative expenses	(16,248)	(17,848)
Otherexpenses	(2,652)	(4,215)
Otherincome	1,724	453
Net foreign exchange transactions gains (losses)	(3,120)	(5,752)
Operating profit	6,773	(33,315)
Share of gain (loss) of associated companies	141	211
Finance income	249	67
Finance costs	(35,651)	(23,543)
Profit (loss) before income tax	(28,488)	(56,580)
Income tax	(875)	(20)
Deferred income tax	5,717	4,023
Profit (loss) for the period	(23,646)	(52,577)
EBITDA before fair value adjustment	52,257	39,387

Financial statements - Balance sheet

Provide a solution from the second solution

|--|

	For the period	For the period For the period		
	30.09.2023*	30.06.2023*		
Assets				
Non-current assets				
Property, plant and equipment, net	741,665	737,782		
Right of use asset	38 <i>,</i> 855	40,773		
Investments in associated companies	4,649	5,271		
Intangibles	12,534	12,885		
Deferred income tax	15,986	14,628		
Other accounts receivable	408	408		
	814,097	811,747		
Current assets				
Assets held for sale	-	-		
Prepaid expenses	2,124	2,101		
Current portion of biological assets	172,313	172,404		
Inventories	51 <i>,</i> 854	52,966		
Other accounts receivable	25,937	23,786		
Trade accounts receivable	14,865	12,054		
Cash subject to restriction	-	-		
Cash and cash equivalents	22,238	28,094		
	289,331	291,405		
Total assets	1,103,428	1,103,152		

		For the period For the period 30.09.2023* 30.06.2023*		
Equity and liabilities	30.03.2023	50.00.2025		
Capital and reserve attributable to				
shareholders of the Company				
Share capital	10,000	10,000		
Revaluation of assets	170,826	170,092		
Retained earnings	82,798	80,994		
-	263,624	261,086		
Minority interests	- 989	- 989		
Total equity	262,635	260,097		
Non-current liabilities				
Long-term debt	356,561	356,735		
Lease liability	74,443	57,924		
Deferred income tax	123,160	123,189		
	554,164	537,848		
Current liabilities				
Accounts payable to related companies	33	32		
Current portion of long-term debt	3,087	7,815		
Current portion of lease liability	21,576	15,739		
Trade payables	91,136	77,723		
Other payables	20,495	20,577		
Bank loans	150,302	183,321		
	286,629	305,207		
Total liabilities	840,793	843,055		
Total equity and liabilities	1,103,428	1,103,152		







Búscanos como CamposolCares en:



Búscanos como Camposol en:

in

Para mas información por favor conectarse a : www.camposol.com.pe

> For more information please log into www.camposol.com.pe